EA202092454A1 - Способы и композиции для количественного определения il-33 - Google Patents
Способы и композиции для количественного определения il-33Info
- Publication number
- EA202092454A1 EA202092454A1 EA202092454A EA202092454A EA202092454A1 EA 202092454 A1 EA202092454 A1 EA 202092454A1 EA 202092454 A EA202092454 A EA 202092454A EA 202092454 A EA202092454 A EA 202092454A EA 202092454 A1 EA202092454 A1 EA 202092454A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- sample
- soluble
- compositions
- methods
- assays
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 3
- 108090000695 Cytokines Proteins 0.000 abstract 3
- 238000003556 assay Methods 0.000 abstract 3
- 239000002981 blocking agent Substances 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 238000003018 immunoassay Methods 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
Abstract
Предложены способы и композиции для обнаружения и количественного определения цитокинов. В описанных анализах по сравнению с коммерчески доступными анализами и/или контрольными анализами уменьшена интерференция. Взаимодействие может быть цитокин-зависимым, цитокин-независимым или и тем, и другим. В одном варианте осуществления предложен иммуноанализ IL-33, в котором снижена интерференция, вызываемая эндогенными растворимыми связывающими IL-33 молекулами, присутствующими в образце. Примеры растворимых связывающих IL-33 молекул включают, но не ограничиваются ими, антитела против IL-33, растворимый рецептор ST2 и компоненты сыворотки. В некоторых вариантах осуществления к образцу добавляют блокирующий агент для уменьшения, ингибирования или блокирования комплексов IL-33 в образце от преобразования после кислотной диссоциации комплексов IL-33 в образце. В одном варианте осуществления блокирующий агент и реагент для обнаружения не конкурируют за связывание с IL-33.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862655887P | 2018-04-11 | 2018-04-11 | |
| PCT/US2019/026699 WO2019199910A1 (en) | 2018-04-11 | 2019-04-10 | Methods for quantifying il-33 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202092454A1 true EA202092454A1 (ru) | 2021-01-15 |
Family
ID=66287025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202092454A EA202092454A1 (ru) | 2018-04-11 | 2019-04-10 | Способы и композиции для количественного определения il-33 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12092634B2 (ru) |
| EP (1) | EP3775898A1 (ru) |
| JP (2) | JP7328250B2 (ru) |
| KR (1) | KR20200142014A (ru) |
| CN (2) | CN111954814B (ru) |
| AU (1) | AU2019251973A1 (ru) |
| BR (1) | BR112020020686A2 (ru) |
| CA (1) | CA3095786A1 (ru) |
| EA (1) | EA202092454A1 (ru) |
| IL (2) | IL277890B2 (ru) |
| MX (1) | MX2020010714A (ru) |
| SG (1) | SG11202009590WA (ru) |
| WO (1) | WO2019199910A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202409562A (zh) * | 2022-07-13 | 2024-03-01 | 美商再生元醫藥公司 | 用於偵測分析物的弱酸免疫分析 |
| CN117054663A (zh) * | 2023-08-01 | 2023-11-14 | 湖南卓润生物科技有限公司 | 检测可溶性生长刺激表达基因2蛋白的试剂盒 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323334B1 (en) | 1999-09-24 | 2001-11-27 | Millennium Pharmaceuticals, Inc. | Nucleic acid molecules encoding a 103 gene product and uses therefor |
| NZ549040A (en) | 2004-02-17 | 2009-07-31 | Schering Corp | Use for interleukin-33 (IL33) and the IL-33 receptor complex |
| KR20070012838A (ko) | 2004-05-19 | 2007-01-29 | 가부시끼가이샤 센단세메이가가꾸겐큐죠 | Ｂ형간염 바이러스의 검출방법 |
| US8147817B2 (en) | 2006-05-04 | 2012-04-03 | The Brigham And Women's Hospital, Inc. | IL-33 in the treatment and diagnosis of diseases and disorders |
| US7560530B1 (en) | 2006-07-20 | 2009-07-14 | Schering Corporation | IL-33 receptor |
| EP2062052A4 (en) * | 2006-09-14 | 2010-02-03 | Ge Healthcare Bio Sciences Ab | METHOD FOR DETERMINING ANALYZ CONCENTRATION |
| US20120263709A1 (en) | 2009-09-10 | 2012-10-18 | Schering Corporation | Use of il-33 antagonists to treat fibrotic diseases |
| EP2490024A1 (en) | 2010-12-22 | 2012-08-22 | Proteomika, S.L. | Method to optimize the treatment of patients with biological drugs |
| RU2597288C2 (ru) | 2011-02-23 | 2016-09-10 | Ф. Хоффманн-Ля Рош Аг | Антитела против человеческого il33r и их применение |
| US9212227B2 (en) | 2012-04-30 | 2015-12-15 | Janssen Biotech, Inc. | ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions |
| AR091069A1 (es) | 2012-05-18 | 2014-12-30 | Amgen Inc | Proteinas de union a antigeno dirigidas contra el receptor st2 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| MX364591B (es) | 2013-03-15 | 2019-05-02 | Regeneron Pharma | Antagonistas de il-33 y usos de estos. |
| KR102400060B1 (ko) | 2013-12-26 | 2022-05-19 | 미쓰비시 타나베 파마 코퍼레이션 | 인간 항 il-33 중화 단일클론 항체 |
| CN106103480B (zh) | 2014-01-10 | 2021-10-22 | 安奈普泰斯生物有限公司 | 针对白介素-33(il-33)的抗体 |
| EP3105592B1 (en) * | 2014-02-11 | 2018-10-17 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| NO2785538T3 (ru) | 2014-05-07 | 2018-08-04 | ||
| CA2960297A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| RS61438B1 (sr) | 2015-03-31 | 2021-03-31 | Medimmune Ltd | Novi oblik il33, mutirani oblici il33, antitela, testovi i postupci za njihovu upotrebu |
| SG11201808693WA (en) | 2016-04-27 | 2018-11-29 | Pfizer | Anti-il-33 antibodies, compositions, methods and uses thereof |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| CN107422131A (zh) * | 2017-07-28 | 2017-12-01 | 江苏龙维生物科技有限公司 | 可溶性st2的检测方法及检测试剂盒 |
-
2018
- 2018-04-10 IL IL277890A patent/IL277890B2/en unknown
- 2018-04-10 IL IL307286A patent/IL307286A/en unknown
-
2019
- 2019-04-10 WO PCT/US2019/026699 patent/WO2019199910A1/en unknown
- 2019-04-10 JP JP2020555412A patent/JP7328250B2/ja active Active
- 2019-04-10 SG SG11202009590WA patent/SG11202009590WA/en unknown
- 2019-04-10 CA CA3095786A patent/CA3095786A1/en active Pending
- 2019-04-10 AU AU2019251973A patent/AU2019251973A1/en active Pending
- 2019-04-10 EA EA202092454A patent/EA202092454A1/ru unknown
- 2019-04-10 BR BR112020020686-5A patent/BR112020020686A2/pt unknown
- 2019-04-10 CN CN201980025050.6A patent/CN111954814B/zh active Active
- 2019-04-10 EP EP19719730.4A patent/EP3775898A1/en active Pending
- 2019-04-10 MX MX2020010714A patent/MX2020010714A/es unknown
- 2019-04-10 US US17/046,200 patent/US12092634B2/en active Active
- 2019-04-10 KR KR1020207030235A patent/KR20200142014A/ko not_active Application Discontinuation
- 2019-04-10 CN CN202310628426.0A patent/CN116660522A/zh active Pending
-
2023
- 2023-08-03 JP JP2023126792A patent/JP2023145692A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116660522A (zh) | 2023-08-29 |
| CA3095786A1 (en) | 2019-10-17 |
| IL277890B (en) | 2020-11-30 |
| JP2023145692A (ja) | 2023-10-11 |
| CN111954814B (zh) | 2023-06-16 |
| WO2019199910A1 (en) | 2019-10-17 |
| US12092634B2 (en) | 2024-09-17 |
| MX2020010714A (es) | 2021-01-08 |
| IL277890A (en) | 2020-11-30 |
| IL277890B2 (en) | 2024-03-01 |
| SG11202009590WA (en) | 2020-10-29 |
| BR112020020686A2 (pt) | 2021-01-19 |
| KR20200142014A (ko) | 2020-12-21 |
| AU2019251973A1 (en) | 2020-10-29 |
| US20210033600A1 (en) | 2021-02-04 |
| IL277890B1 (en) | 2023-11-01 |
| IL307286A (en) | 2023-11-01 |
| JP2021521431A (ja) | 2021-08-26 |
| EP3775898A1 (en) | 2021-02-17 |
| CN111954814A (zh) | 2020-11-17 |
| JP7328250B2 (ja) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535015A5 (ru) | ||
| Mahler et al. | Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies | |
| AU2016101432A4 (en) | Chemiluminescence protein chip, kit and method for detecting seroglycoid fucose index | |
| ATE449337T1 (de) | Assay | |
| WO2013132347A3 (en) | Improved elisa immunoassay for calprotectin | |
| RU2008135060A (ru) | Применение гликозаминогликанов для снижения неспецифического связывания в иммунологических анализах | |
| RU2701684C2 (ru) | Анализ конкурентного связывания с лигандом для обнаружения нейтрализирующих антител | |
| RU2011140471A (ru) | Способ диагностики эндометриоза и диагностический набор для эндометриоза | |
| MX2021013519A (es) | Ensayos de union de ligandos competitivos mejorados. | |
| EA202092454A1 (ru) | Способы и композиции для количественного определения il-33 | |
| CN112255406A (zh) | 测定人体高尔基体蛋白含量的磁微粒化学发光检测试剂盒 | |
| Åström et al. | Reverse lectin ELISA for detecting fucosylated forms of α1-acid glycoprotein associated with hepatocellular carcinoma | |
| CN105606822A (zh) | β2-微球蛋白检测试剂盒 | |
| Pan et al. | A magnetic beads-based portable flow cytometry immunosensor for in-situ detection of marine biotoxin | |
| GB2590230A (en) | Methods and kits for detection of 11-dehydro-thromboxane B2 | |
| Sok et al. | Novel fluoroimmunoassay for ovarian cancer biomarker CA-125 | |
| RU2015107740A (ru) | Способ измерения, реагент для измерения и набор для измерения pivka-ii | |
| EP2980586A1 (en) | Insulin assay method | |
| RU2018142846A (ru) | Характерные наборы биомаркеров системной красной волчанки и их применение | |
| Lambert | A novel method of digital ELISA using single molecule amplification enables sub-attomolar detection limits for blood-based proteomics and biomarker measurements | |
| Yang et al. | A biotin–streptavidin signal amplification strategy for a highly sensitive chemiluminescent immunoassay for chicken interferon-γ | |
| Malek-Hosseini et al. | Circulating levels of M30 and M65 molecules in transitional cell carcinoma of the bladder and their relation to tumor progression | |
| JP4657328B2 (ja) | 免疫反応干渉物質の除去方法 | |
| Son et al. | Strategies for the optimization of bead-immunoassays for the effective detection of target biomolecules | |
| WO2020179712A1 (en) | Methods for predicting tumor response to eribulin |